News Releases:

2009

miRagen Announces Discovery of Key microRNA Implicated in Lou Gehrig’s Disease

Findings Could Lead to Novel Therapeutic Intervention Strategies for Neuromuscular Disorders Data published in latest issue of Science BOULDER, Colo., December 10, 2009 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based... View »

miRagen Therapeutics Named 2009 Rising Star of the Year by Colorado BioScience Association

Award Highlights the Company’s Early Achievements BOULDER, Colo., November 19, 2009 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today it had received the... View »

Dr. Thomas E. Hughes Elected to miRagen Board of Directors

BOULDER, Colo., October 15, 2009 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced that Thomas E. Hughes, Ph.D., was elected to its Board... View »

miRagen and Archemix to Collaborate on Conjugated Aptamer-microRNA Therapeutics

BOULDER, Colo. & CAMBRIDGE, Mass., July 23, 2009 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, and Archemix Corp., a biotechnology company focused on developing aptamer therapeutics, announced today... View »

miRagen Therapeutics’ Chief Scientific Advisor Wins Prestigious French Award for Heart Research

Prize Recognizes Seminal Contributions to the Field of Cardiovascular Medicine BOULDER, CO, June 9, 2009—miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced that its... View »

miRagen Therapeutics, Inc. Accomplishes Funding Milestones and Secures Series A Extension

Extension Provides Total Series A Funding of $12 Million BOULDER, CO, June 2, 2009—miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA) based therapeutics for cardiovascular and muscle disease, today announced the... View »